Uzbekistan
Tuberculosis profile
| High MDR-TB burden |
Population  2012 29 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.6 (0.35–0.93) 2.1 (1.2–3.3)
Mortality (HIV+TB only) 0.18 (0.16–0.23) 0.64 (0.55–0.82)
Prevalence  (includes HIV+TB) 39 (19–65) 135 (67–227)
Incidence  (includes HIV+TB) 22 (18–27) 78 (65–93)
Incidence (HIV+TB only) 0.44 (0.37–0.53) 1.6 (1.3–1.9)
Case detection, all forms (%) 66 (56–80)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 4 030 (29) Relapse 655 (25)
Smear-negative 6 137 (43) Treatment after failure 190 (7)
Smear-unknown / not done 0 (0) Treatment after default 27 (1)
Extrapulmonary 3 965 (28) Other 1 761 (67)
Other 0 (0)      
Total new 14 132   Total retreatment 2 633  
           
Other (history unknown) 45        
Total new and relapse 14 787   Total cases notified 16 810  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.3 1.4 1.5
Age < 15 19 221 1 321
Laboratories 2012
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 1.2
Drug susceptibility testing (per 5 million population) 0.5
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 78   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 87  
Retreatment 72  
TB/HIV 2012 Number (%)
TB patients with known HIV status 16 810 (100)
HIV-positive TB patients 820 (5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 779 (95)
HIV-positive TB patients on antiretroviral therapy (ART) 103 (13)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 2 010  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 23 (18–29) 62 (52–71)
MDR-TB cases among notified pulmonary
TB cases
2 400 (1 800–3 000) 1 600 (1 400–1 900)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 2 524 (52%) 1 025 (39%) 4 217
Laboratory-confirmed MDR-TB cases 703 479 1 728
Patients started on MDR-TB treatment     1 491
Financing TB control 2013
National TB programme budget (US$ millions) 76
% Funded domestically 75%
% Funded internationally 25%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-16 Data: www.who.int/tb/data